Exelixis, Inc. (EXEL)

21,93 +0,24 (+1,11%) Alla chiusura: 04:00PM EDT

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000
https://www.exelixis.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1.310

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Stelios Papadopoulos Ph.D.	Co-Founder & Chair of the Board	118,25k	N/D	1948
Dr. Michael M. Morrissey Ph.D.	CEO, President & Director	2,16M	3,79M	1961
Mr. Christopher J. Senner	Executive VP & CFO	1,06M	702,51k	1968
Dr. Dana T. Aftab Ph.D.	Executive VP of Discovery and Translational Research & Chief Scientific Officer	883,03k	227,7k	1964
Mr. Jeffrey J. Hessekiel J.D.	Executive VP, General Counsel & Secretary	933,08k	412,51k	1969
Dr. Amy C. Peterson M.D.	Executive VP, Product Development & Medical Affairs and Chief Medical Officer	568,85k	N/D	1967
Ms. Susan T. Hubbard	Executive Vice President of Public Affairs & Investor Relations	N/D	N/D	N/D
Ms. Laura Dillard	Executive Vice President of Human Resources	N/D	N/D	N/D
Dr. Anne Champsaur M.D.	Senior Vice President of Drug Safety	N/D	N/D	N/D
Dr. William Berg M.D.	Senior Vice President of Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Governance aziendale

L'ISS Governance QualityScore di Exelixis, Inc. al 1 giugno 2024 è 2. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 1; diritti degli azionisti: 4; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.